Lustgarten’s partnership with the Cancer Research Institute (CRI) has created an initiative that focuses exclusively on supporting pancreatic cancer immunotherapy research.
INSPIRE (Integrated Network for Supporting Pancreatic Cancer Immunotherapy Research Efforts) encompasses the established and ongoing adaptive platform trial, REVOLUTION, evaluating first-line chemo-immunotherapy treatment combinations for patients with metastatic pancreatic adenocarcinoma. Designed for flexibility, the trial allows researchers to test multiple hypotheses in parallel, leveraging clinical and translational data to inform decision-making and ensure they are embarking on the best next steps.
Beyond REVOLUTION, the partnership is expanding into new areas of pancreatic immunotherapy research, reflecting a shared commitment to transforming pancreatic cancer into a curable disease.
“For patients with pancreatic cancer, we are activating the immune system in a way we have not before, and we are doing that selectively. Novel combinations of chemotherapy and immunotherapy may work together to offer benefit for patients with pancreatic cancer…”
–Robert H. Vonderheide, MD, DPhil, director of the Abramson Cancer Center at the University of Pennsylvania and overall principal investigator for REVOLUTION